Literature DB >> 27212031

Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia.

G B Martinelli1, D Olivari1, A D Re Cecconi1, L Talamini1, L Ottoboni2, S H Lecker3, C Stretch4, V E Baracos4, O F Bathe5, A Resovi6, R Giavazzi1, L Cervo7, R Piccirillo1.   

Abstract

Cancer cachexia is a life-threatening syndrome that affects most patients with advanced cancers and causes severe body weight loss, with rapid depletion of skeletal muscle. No treatment is available. We analyzed microarray data sets to identify a subset of genes whose expression is specifically altered in cachectic muscles of Yoshida hepatoma-bearing rodents but not in those with diabetes, disuse, uremia or fasting. Ingenuity Pathways Analysis indicated that three genes belonging to the C-X-C motif chemokine receptor 4 (CXCR4) pathway were downregulated only in muscles atrophying because of cancer: stromal cell-derived factor 1 (SDF1), adenylate cyclase 7 (ADCY7), and p21 protein-activated kinase 1 (PAK1). Notably, we found that, in the Rectus Abdominis muscle of cancer patients, the expression of SDF1 and CXCR4 was inversely correlated with that of two ubiquitin ligases induced in muscle wasting, atrogin-1 and MuRF1, suggesting a possible clinical relevance of this pathway. The expression of all main SDF1 isoforms (α, β, γ) also declined in Tibialis Anterior muscle from cachectic mice bearing murine colon adenocarcinoma or human renal cancer and drugs with anticachexia properties restored their expression. Overexpressing genes of this pathway (that is, SDF1 or CXCR4) in cachectic muscles increased the fiber area by 20%, protecting them from wasting. Similarly, atrophying myotubes treated with either SDF1α or SDF1β had greater total protein content, resulting from reduced degradation of overall long-lived proteins. However, inhibiting CXCR4 signaling with the antagonist AMD3100 did not affect protein homeostasis in atrophying myotubes, whereas normal myotubes treated with AMD3100 showed time- and dose-dependent reductions in diameter, until a plateau, and lower total protein content. This further confirms the involvement of a saturable pathway (that is, CXCR4). Overall, these findings support the idea that activating the CXCR4 pathway in muscle suppresses the deleterious wasting associated with cancer.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27212031     DOI: 10.1038/onc.2016.153

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  50 in total

1.  The p97/VCP ATPase is critical in muscle atrophy and the accelerated degradation of muscle proteins.

Authors:  Rosanna Piccirillo; Alfred L Goldberg
Journal:  EMBO J       Date:  2012-07-06       Impact factor: 11.598

2.  Effect of sera from fed and fasted pigs on proliferation and protein turnover in cultured myogenic cells.

Authors:  M E White; C E Allen; W R Dayton
Journal:  J Anim Sci       Date:  1988-01       Impact factor: 3.159

Review 3.  How many drug targets are there?

Authors:  John P Overington; Bissan Al-Lazikani; Andrew L Hopkins
Journal:  Nat Rev Drug Discov       Date:  2006-12       Impact factor: 84.694

Review 4.  Protein degradation by the ubiquitin-proteasome pathway in normal and disease states.

Authors:  Stewart H Lecker; Alfred L Goldberg; William E Mitch
Journal:  J Am Soc Nephrol       Date:  2006-05-31       Impact factor: 10.121

Review 5.  Functional diversity of SDF-1 splicing variants.

Authors:  Miroslaw Janowski
Journal:  Cell Adh Migr       Date:  2009-07-23       Impact factor: 3.405

6.  Interleukin 6 is associated with cachexia in patients with prostate cancer.

Authors:  Kenji Kuroda; Jun Nakashima; Kent Kanao; Eiji Kikuchi; Akira Miyajima; Yutaka Horiguchi; Ken Nakagawa; Mototsugu Oya; Takashi Ohigashi; Masaru Murai
Journal:  Urology       Date:  2007-01       Impact factor: 2.649

7.  Induction of myogenic differentiation by SDF-1 via CXCR4 and CXCR7 receptors.

Authors:  Roberta Melchionna; Anna Di Carlo; Roberta De Mori; Claudia Cappuzzello; Laura Barberi; Antonio Musarò; Chiara Cencioni; Nobutaka Fujii; Hirokazu Tamamura; Marco Crescenzi; Maurizio C Capogrossi; Monica Napolitano; Antonia Germani
Journal:  Muscle Nerve       Date:  2010-06       Impact factor: 3.217

8.  Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma.

Authors:  M Oka; K Yamamoto; M Takahashi; M Hakozaki; T Abe; N Iizuka; S Hazama; K Hirazawa; H Hayashi; A Tangoku; K Hirose; T Ishihara; T Suzuki
Journal:  Cancer Res       Date:  1996-06-15       Impact factor: 12.701

9.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

Authors:  W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

10.  The chemokine Sdf-1 and its receptor Cxcr4 are required for formation of muscle in zebrafish.

Authors:  Shang-Wei Chong; Le-Minh Nguyet; Yun-Jin Jiang; Vladimir Korzh
Journal:  BMC Dev Biol       Date:  2007-05-22       Impact factor: 1.978

View more
  16 in total

1.  Cardiovascular disease related circulating biomarkers and cancer incidence and mortality: is there an association?

Authors:  Manol Jovani; Elizabeth E Liu; Samantha M Paniagua; Emily S Lau; Shawn X Li; Katherine S Takvorian; Bernard E Kreger; Greta Lee Splansky; Rudolf A de Boer; Amit D Joshi; Shih Jen Hwang; Chen Yao; Tianxiao Huan; Paul Courchesne; Martin G Larson; Daniel Levy; Andrew T Chan; Jennifer E Ho
Journal:  Cardiovasc Res       Date:  2022-07-27       Impact factor: 13.081

2.  Micro-computed tomography for non-invasive evaluation of muscle atrophy in mouse models of disease.

Authors:  Laura Pasetto; Davide Olivari; Giovanni Nardo; Maria Chiara Trolese; Caterina Bendotti; Rosanna Piccirillo; Valentina Bonetto
Journal:  PLoS One       Date:  2018-05-29       Impact factor: 3.240

3.  Group I Paks support muscle regeneration and counteract cancer-associated muscle atrophy.

Authors:  Andrea Cerquone Perpetuini; Andrea David Re Cecconi; Michela Chiappa; Giulia Benedetta Martinelli; Claudia Fuoco; Giovanni Desiderio; Luisa Castagnoli; Cesare Gargioli; Rosanna Piccirillo; Gianni Cesareni
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-05-21       Impact factor: 12.910

4.  Defective angiogenesis in CXCL12 mutant mice impairs skeletal muscle regeneration.

Authors:  David Hardy; Mylène Fefeu; Aurore Besnard; David Briand; Paméla Gasse; Fernando Arenzana-Seisdedos; Pierre Rocheteau; Fabrice Chrétien
Journal:  Skelet Muscle       Date:  2019-09-18       Impact factor: 4.912

5.  Musclin, A Myokine Induced by Aerobic Exercise, Retards Muscle Atrophy During Cancer Cachexia in Mice.

Authors:  Andrea D Re Cecconi; Mara Forti; Michela Chiappa; Zhiyong Zhu; Leonid V Zingman; Luigi Cervo; Luca Beltrame; Sergio Marchini; Rosanna Piccirillo
Journal:  Cancers (Basel)       Date:  2019-10-12       Impact factor: 6.639

6.  p21-Activated Kinase 1 Is Permissive for the Skeletal Muscle Hypertrophy Induced by Myostatin Inhibition.

Authors:  Caroline Barbé; Audrey Loumaye; Pascale Lause; Olli Ritvos; Jean-Paul Thissen
Journal:  Front Physiol       Date:  2021-06-17       Impact factor: 4.566

7.  Differentially expressed alternatively spliced genes in skeletal muscle from cancer patients with cachexia.

Authors:  Ashok Narasimhan; Russell Greiner; Oliver F Bathe; Vickie Baracos; Sambasivarao Damaraju
Journal:  J Cachexia Sarcopenia Muscle       Date:  2017-10-06       Impact factor: 12.910

8.  Oxidation of HMGB1 Is a Dynamically Regulated Process in Physiological and Pathological Conditions.

Authors:  Michele Ferrara; Ginevra Chialli; Lorena Maria Ferreira; Elena Ruggieri; Giorgia Careccia; Alessandro Preti; Rosanna Piccirillo; Marco Emilio Bianchi; Giovanni Sitia; Emilie Venereau
Journal:  Front Immunol       Date:  2020-06-24       Impact factor: 7.561

Review 9.  Metabolic reprogramming in tumors: Contributions of the tumor microenvironment.

Authors:  Andrew N Lane; Richard M Higashi; Teresa W-M Fan
Journal:  Genes Dis       Date:  2019-10-23

Review 10.  Molecular mechanisms of cancer cachexia‑induced muscle atrophy (Review).

Authors:  Wei Yang; Jianhui Huang; Hui Wu; Yuqing Wang; Zhiyin Du; Yuanbo Ling; Weizhuo Wang; Qian Wu; Wenbin Gao
Journal:  Mol Med Rep       Date:  2020-10-16       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.